Cancer Screening & PreventionJuly 21, 2026·5 min read
By the CIRRUS Editorial Team — how we write and source this
Prostate cancer screening: the PSA test controversy, explained plainly
Few screening tests have swung as sharply between broad recommendation and broad caution as PSA testing. What the actual controversy is about, and where current guidance has landed.
PSA (prostate-specific antigen) screening has swung between broad recommendation and broad caution more sharply than most cancer screening tests, and understanding why requires understanding what the controversy is actually about: it's not a dispute over whether PSA testing can detect prostate cancer — it reliably does — but over whether that early detection meaningfully reduces prostate cancer deaths once the risks of overdiagnosis and overtreatment are properly weighed against that benefit.
The overdiagnosis concern is the crux of the issue: prostate cancer, more than most cancer types, includes a meaningful proportion of slow-growing tumors that would never have caused symptoms or death within a man's natural lifespan even without treatment, and PSA screening detects these indolent cancers alongside the more aggressive ones — meaning a share of men diagnosed through screening undergo the real risks and side effects of prostate cancer treatment (including incontinence and erectile dysfunction) for a cancer that, left undetected, may never have caused them harm.
Current guidance from major medical organizations has generally moved toward a shared decision-making framework rather than either a blanket recommendation for or against routine PSA screening — meaning the decision is framed as an individualized discussion between a man and his physician, weighing personal risk factors (family history, race, since Black men face measurably higher prostate cancer risk and mortality), personal values around the overdiagnosis-overtreatment tradeoff, and life expectancy considerations, rather than a uniform recommendation applied to every man in a given age range.
This shared decision-making approach is a meaningfully different message than either the earlier era's broad routine screening recommendation or the subsequent period of broader caution against screening, and it reflects that reasonable, well-informed men can weigh this specific tradeoff differently based on their own risk profile and personal values — which is exactly why the conversation with a physician about individual risk factors matters more here than in cancer screenings with a more straightforward, universally favorable risk-benefit balance.
This article is general health information, not medical advice, and doesn’t replace evaluation by your own physician. Talk to a doctor about anything specific to your own diagnosis or treatment.